CA2538887A1 - Measles subunit vaccine - Google Patents

Measles subunit vaccine Download PDF

Info

Publication number
CA2538887A1
CA2538887A1 CA002538887A CA2538887A CA2538887A1 CA 2538887 A1 CA2538887 A1 CA 2538887A1 CA 002538887 A CA002538887 A CA 002538887A CA 2538887 A CA2538887 A CA 2538887A CA 2538887 A1 CA2538887 A1 CA 2538887A1
Authority
CA
Canada
Prior art keywords
immunogenic composition
antigen
measles
composition according
proteosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002538887A
Other languages
English (en)
French (fr)
Inventor
David S. Burt
Brian J. Ward
Sophie Chabot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
ID Biomedical Corp of Quebec
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2538887A1 publication Critical patent/CA2538887A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002538887A 2003-09-15 2004-09-15 Measles subunit vaccine Abandoned CA2538887A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50311403P 2003-09-15 2003-09-15
US60/503,114 2003-09-15
PCT/US2004/030361 WO2005027964A1 (en) 2003-09-15 2004-09-15 Measles subunit vaccine

Publications (1)

Publication Number Publication Date
CA2538887A1 true CA2538887A1 (en) 2005-03-31

Family

ID=34375312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002538887A Abandoned CA2538887A1 (en) 2003-09-15 2004-09-15 Measles subunit vaccine

Country Status (5)

Country Link
US (2) US20050152919A1 (enExample)
EP (1) EP1667713A1 (enExample)
JP (1) JP2007505836A (enExample)
CA (1) CA2538887A1 (enExample)
WO (1) WO2005027964A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
WO2009132244A1 (en) * 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Methods for preparing immunogenic compositions
JP2010122205A (ja) * 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
US10092642B2 (en) 2013-10-03 2018-10-09 Nitto Denko Corporation Mucosal vaccine composition
JP6494233B2 (ja) * 2013-10-03 2019-04-03 日東電工株式会社 粘膜ワクチン組成物
CN105530953A (zh) * 2013-10-03 2016-04-27 日东电工株式会社 注射疫苗组合物
KR20160061989A (ko) 2013-10-03 2016-06-01 닛토덴코 가부시키가이샤 코점막 백신 조성물
TW201618790A (zh) * 2014-10-02 2016-06-01 Nitto Denko Corp 經皮投與用疫苗醫藥組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
NZ500779A (en) * 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6262029B1 (en) * 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
GB9925966D0 (en) * 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
DE19963124A1 (de) * 1999-12-24 2001-07-12 Roland Man Druckmasch Reinigungsmedium und dessen Verwendung
AUPQ520800A0 (en) * 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
JP2003528068A (ja) * 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant

Also Published As

Publication number Publication date
US20090175903A1 (en) 2009-07-09
US20050152919A1 (en) 2005-07-14
WO2005027964A1 (en) 2005-03-31
JP2007505836A (ja) 2007-03-15
EP1667713A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
US20090175903A1 (en) Measles subunit vaccine
JP4137640B2 (ja) 新規プロテオソーム−リポサッカリドワクチンアジュバント
ES2307494T3 (es) Vacuna del virus de la gripe inactivo para su administracion via nasalu oral.
Hirabayashi et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination
EP0528859B1 (en) Oral vaccine comprising antigen surface-associated with red blood cells
US8182821B2 (en) Flu vaccine admixture of mannan and flu antigen
KR100764678B1 (ko) 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
JP2007505033A (ja) 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン
JP4021146B2 (ja) Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物
Yang et al. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum
Chabot et al. A novel intranasal Protollin™-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice
AU674983B2 (en) Vaccine compositions
TW202228770A (zh) 具有含有生育酚之鯊烯乳劑佐劑之covid-19疫苗
Uchida et al. Application of surface-linked liposomal antigens to the development of vaccines that induce both humoral and cellular immunity
US20060110740A1 (en) Use of sendai virus as a human parainfluenza vaccine
US20240197865A1 (en) Compositions and methods for preventing rsv and piv3 infections
JP4889175B2 (ja) 感染性因子に対する免疫応答を刺激するための組成物および方法
WO2008037033A1 (en) Flu vaccine admixture of mannan and flu antigen
KR20090016659A (ko) 비로좀을 기제로 한 비강내 인플루엔자 백신
JP2020050605A (ja) 粘膜アジュバント
WO2004098636A2 (en) Vaccinating against infectious diseases using proteosomes
JP2023518427A (ja) ハプテン化コロナウイルススパイクタンパク質
Jazayeri et al. Evaluation of cross immune response in DNA based vaccinated mice against HSV-1 and HSV-2
MX2008012046A (es) Vacuna intranasal contra la influenza, basada en virosomas.
HK1151733B (en) Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same

Legal Events

Date Code Title Description
FZDE Discontinued